Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
metformin hydrochloride, Quantity: 1000 mg; sitagliptin phosphate monohydrate, Quantity: 64.25 mg (Equivalent: sitagliptin, Qty 50 mg)
Merck Sharp & Dohme (Australia) Pty Ltd
Metformin hydrochloride,sitagliptin phosphate monohydrate
Tablet, modified release
Excipient Ingredients: povidone; colloidal anhydrous silica; hypromellose; kaolin; propyl gallate; sodium stearylfumarate; macrogol 3350; Carnauba Wax; titanium dioxide; hyprolose; iron oxide yellow; indigo carmine aluminium lake
Oral
14 tablets - starter pack, 56 tablets
(S4) Prescription Only Medicine
VELMETIA XR (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see Sections 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials and 4.2 DOSE AND METHOD OF ADMINISTRATION].
Visual Identification: Light green, bi-convex oval, film coated tablet, debossed "80" on one side and plain on the other.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2014-11-19